Mark Pruzanski, CEO & President at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 12,500 shares at $252.53 ($3.2M) on 2015-05-01, disclosed to the SEC on 2015-05-05.
Scheduled sale ($3.2M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $251.39 | 1,700 | $427K | 13.5% |
| 2 | $252.53 | 3,350 | $846K | 26.7% |
| 3 | $253.52 | 4,338 | $1.1M | 34.7% |
| 4 | $254.63 | 1,539 | $392K | 12.4% |
| 5 | $255.49 | 661 | $169K | 5.3% |
| 6 | $256.42 | 200 |
| $51K |
| 1.6% |
| 7 | $258.50 | 400 | $103K | 3.3% |
| 8 | $259.33 | 312 | $81K | 2.6% |
| Total | $253.56 avg | 12,500 | $3.2M | 100% |
| Filing → |
| ICPT | SELL | 2019-11-27 | $5.0M | — | Filing → |
| ICPT | SELL | 2018-11-16 | $9.1M | — | Filing → |
| ICPT | BUY | 2018-04-09 | $500K | — | Filing → |